Swallowing a bitter pill-oral arsenic trioxide for acute promyelocytic leukemia.

Abstract:

:Parenteral arsenic trioxide (ATO) has been firmly established as a standard therapy for acute promyelocytic leukemia (APL). Despite widespread use of oral arsenicals in medicine historically, they had disappeared from modern pharmacopeia until oral ATO was redeveloped in Hong Kong in 2000. Since then, over 200 patients with leukemia (predominantly APL) have been treated with oral ATO in Hong Kong and China. Oral arsenic trioxide and other formulations of arsenic appear to have a clinical efficacy comparable to that of IV formulations. These drugs given orally also appear to have a slightly better safety profile, lower operational costs and improved convenience for patients. The clinical experience with oral ATO has previously been reported piecemeal as case series, pilot studies or subgroup analyses rather than in a comprehensive cohort. In this report we attempt to synthesize the published English language literature on oral arsenicals and present the argument for further development of these compounds. Systematic study of this drug with well-designed randomized multi-center clinical trials is needed to accelerate its development and incorporation into clinical practice.

journal_name

Blood Rev

journal_title

Blood reviews

authors

Torka P,Al Ustwani O,Wetzler M,Wang ES,Griffiths EA

doi

10.1016/j.blre.2015.11.004

subject

Has Abstract

pub_date

2016-05-01 00:00:00

pages

201-11

issue

3

eissn

0268-960X

issn

1532-1681

pii

S0268-960X(15)00092-2

journal_volume

30

pub_type

杂志文章,评审
  • What can we learn from ineffective erythropoiesis in thalassemia?

    abstract::Erythropoiesis is a dynamic process regulated at multiple levels to balance proliferation, differentiation and survival of erythroid progenitors. Ineffective erythropoiesis is a key feature of various diseases, including β-thalassemia. The pathogenic mechanisms leading to ineffective erythropoiesis are complex and sti...

    journal_title:Blood reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.blre.2017.10.001

    authors: Oikonomidou PR,Rivella S

    更新日期:2018-03-01 00:00:00

  • Enzyme therapy for Gaucher disease: the first 5 years.

    abstract::Gaucher disease was first described by Philippe Gaucher in his 1882 medical thesis. Gaucher's original concept was of an unusual epithelioma of the spleen. By the early 1900s, Mandelbaum recognized the systemic nature of the disease. Several children with Gaucher disease were described at the turn of the century, but ...

    journal_title:Blood reviews

    pub_type: 杂志文章,评审

    doi:10.1016/s0268-960x(98)90023-6

    authors: Grabowski GA,Leslie N,Wenstrup R

    更新日期:1998-06-01 00:00:00

  • Antithrombin III deficiency.

    abstract::A moderate reduction of plasma antithrombin activity is an uncommon but clinically important cause of severe thromboembolic disease. In recent years the molecule responsible for the major part of this activity (antithrombin III) has been extensively characterised and the mode of inheritance of familial deficiencies wo...

    journal_title:Blood reviews

    pub_type: 杂志文章,评审

    doi:10.1016/0268-960x(88)90013-6

    authors: Beresford CH

    更新日期:1988-12-01 00:00:00

  • Biochemistry of factor X.

    abstract::Factor X circulates as a serine protease which is converted to the active form at the point of convergence of the intrinsic and extrinsic coagulation pathways. Subsequently, the enzymatic species, factor Xa, is involved in macromolecular complex formation with its cofactor factor Va, a phospholipid surface and calcium...

    journal_title:Blood reviews

    pub_type: 杂志文章,评审

    doi:10.1016/0268-960x(94)90007-8

    authors: Hertzberg M

    更新日期:1994-03-01 00:00:00

  • The role of tissue factor pathway inhibitor in atherosclerosis and arterial thrombosis.

    abstract::Tissue factor pathway inhibitor (TFPI) is the main inhibitor of tissue factor (TF)-mediated coagulation. In atherosclerotic plaques TFPI co-localizes with TF, where it is believed to play an important role in attenuating TF activity. Findings in animal models such as TFPI knockout models and gene transfer models are c...

    journal_title:Blood reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.blre.2013.03.001

    authors: Winckers K,ten Cate H,Hackeng TM

    更新日期:2013-05-01 00:00:00

  • The definition and epidemiology of non-transfusion-dependent thalassemia.

    abstract::Inherited hemoglobin-related disorders, which include the structural variants (hemoglobin S, C, and E) and the alpha (α)- and beta (β)-thalassemias, affect more than 300,000 children annually, particularly in malaria-endemic regions stretching from sub-Saharan Africa and the Mediterranean to Southeast Asia. Screening ...

    journal_title:Blood reviews

    pub_type: 杂志文章,评审

    doi:10.1016/S0268-960X(12)70003-6

    authors: Weatherall DJ

    更新日期:2012-04-01 00:00:00

  • Mechanisms of extramedullary relapse in acute lymphoblastic leukemia: Reconciling biological concepts and clinical issues.

    abstract::Long-term survival rates in childhood acute lymphoblastic leukemia (ALL) are currently above 85% due to huge improvements in treatment. However, 15-20% of children still experience relapses. Relapses can either occur in the bone marrow or at extramedullary sites, such as gonads or the central nervous system (CNS), for...

    journal_title:Blood reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.blre.2019.04.003

    authors: Gaudichon J,Jakobczyk H,Debaize L,Cousin E,Galibert MD,Troadec MB,Gandemer V

    更新日期:2019-07-01 00:00:00

  • Extracorporeal photopheresis: a review.

    abstract::Extracorporeal phototherapy (ECP) is a therapeutic approach based on the biological effect of psoralen 8-methoxypsoralen (8-MOP) and ultraviolet light A (UVA) on mononuclear cells collected by apheresis, and reinfused into the patient. Photopheresis is widely used for the treatment of patients with advanced cutaneous ...

    journal_title:Blood reviews

    pub_type: 杂志文章,评审

    doi:10.1054/blre.2001.0155

    authors: Oliven A,Shechter Y

    更新日期:2001-06-01 00:00:00

  • Results of programmes for antenatal detection of thalassemia in reducing the incidence of the disorder.

    abstract::The characteristics and the effectiveness of programmes designed to prevent beta-thalassemia major present in high frequency in several areas of the world such as Cyprus, Greece and Sardinia are reviewed. All these programmes are based on heterozygote detection, counselling and foetal diagnosis. The target population ...

    journal_title:Blood reviews

    pub_type: 杂志文章,评审

    doi:10.1016/0268-960x(87)90032-4

    authors: Cao A

    更新日期:1987-09-01 00:00:00

  • Thrombophilia and fetal loss.

    abstract::Recurrent fetal loss and other placental vascular pathologies of pregnancy have long been associated with antiphospholipid syndrome-an acquired autoimmune thrombophilic state. The number of known heritable thrombophilic disorders has grown rapidly in recent years with the identification of activated protein C resistan...

    journal_title:Blood reviews

    pub_type: 杂志文章,评审

    doi:10.1016/s0268-960x(97)90013-8

    authors: Brenner B,Blumenfeld Z

    更新日期:1997-06-01 00:00:00

  • Venous thromboembolism incidence in hematologic malignancies.

    abstract::Venous thromboembolism (VTE) remains a major cause of morbidity and mortality in patients with cancer. Although some very well validated scores delineate the risk of VTE by cancer subtype and other risk factors, hematologic malignancies are underrepresented in these models. This subgroup represents a unique entity tha...

    journal_title:Blood reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.blre.2018.06.002

    authors: Kekre N,Connors JM

    更新日期:2019-01-01 00:00:00

  • Myeloid-derived suppressor cells in lymphoma: The good, the bad and the ugly.

    abstract::Lymphomas cause significant morbidity and mortality worldwide. A substantial number of patients ultimately relapse after standard treatment. However, the efficacy of these therapies can be counteracted by the patients' immune system, more specifically by myeloid-derived suppressor cells (MDSC). MDSC are a heterogeneou...

    journal_title:Blood reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.blre.2018.04.006

    authors: Betsch A,Rutgeerts O,Fevery S,Sprangers B,Verhoef G,Dierickx D,Beckers M

    更新日期:2018-11-01 00:00:00

  • Microarray-based gene expression profiling of hematologic malignancies: basic concepts and clinical applications.

    abstract::Each cell in our body contains a set of tens of thousands of genes, out of which a set of several thousands determines the cell's characteristics. The deciphering of the sequence of the human genome combined with the technical feasibility to simultaneously measure the gene expression levels of thousands of genes had r...

    journal_title:Blood reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.blre.2004.11.003

    authors: Margalit O,Somech R,Amariglio N,Rechavi G

    更新日期:2005-07-01 00:00:00

  • Myelodysplasic syndromes: a comprehensive review.

    abstract::Myelodysplastic syndromes (MDS) are a set of oligoclonal disorders of hematopoietic stem cells characterized by ineffective hematopoiesis that manifest clinically as anemia, neutropenia, and/or thrombocytopenia of variable severity. The result often is transfusion-dependent anemia, an increased risk of infection or he...

    journal_title:Blood reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.blre.2005.01.004

    authors: Catenacci DV,Schiller GJ

    更新日期:2005-11-01 00:00:00

  • Management of challenging myelofibrosis after JAK inhibitor failure and/or progression.

    abstract::The myeloproliferative neoplasms (MPNs) encompass a heterogenous set of diseases that have variable survival, but in the setting of treatment refractory and progressive disease, prognosis has been characteristically poor. JAK inhibition with ruxolitinib or fedratinib therapy has become the first line treatment for sym...

    journal_title:Blood reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.blre.2020.100716

    authors: Scherber RM,Mesa RA

    更新日期:2020-07-01 00:00:00

  • Genomic signatures in B-cell lymphoma: How can these improve precision in diagnosis and inform prognosis?

    abstract::Current genomic technologies have immensely improved disease classification and prognostication of major subtypes of B-cell lymphomas. This novel genetic information has not only aided in diagnosis, but has also revealed a landscape of critical molecular events that determine the biological and clinical behavior of a ...

    journal_title:Blood reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.blre.2015.08.002

    authors: Iqbal J,Naushad H,Bi C,Yu J,Bouska A,Rohr J,Chao W,Fu K,Chan WC,Vose JM

    更新日期:2016-03-01 00:00:00

  • Management of venous thromboembolism in athletes.

    abstract::Venous thromboembolism (VTE) is a common condition with high associated morbidity and mortality. Athletes have unique VTE risk factors compared with the general population, and may have a higher than anticipated risk of thrombosis. Anticoagulant treatment poses additional challenges in athletes, as these individuals u...

    journal_title:Blood reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.blre.2020.100780

    authors: Swan D,Carter-Brzezinski L,Thachil J

    更新日期:2020-11-15 00:00:00

  • Infection control in patients with myelodysplastic syndromes who are candidates for active treatment: Expert panel consensus-based recommendations.

    abstract::The improvement in supportive care and the introduction of new therapeutic agents, including lenalidomide and hypomethylating agents, in myelodysplastic syndromes have improved patients' outcomes; however, at the same time, the frequency and epidemiology of infections have changed. Therefore, the great strides in the ...

    journal_title:Blood reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.blre.2018.10.002

    authors: Girmenia C,Candoni A,Delia M,Latagliata R,Molteni A,Oliva EN,Palumbo GA,Poloni A,Salutari P,Santini V,Voso MT,Musto P

    更新日期:2019-03-01 00:00:00

  • Current opinion in essential thrombocythemia: pathogenesis, diagnosis, and management.

    abstract::A working diagnosis of essential thrombocythemia (ET) is made in the presence of nonreactive thrombocytosis and after the exclusion of another chronic myeloid disorder that may mimic ET in its presentation. Clinically, ET is characterized by vasomotor symptoms, thrombohemorrhagic complications, recurrent fetal loss, a...

    journal_title:Blood reviews

    pub_type: 杂志文章,评审

    doi:10.1054/blre.2001.0158

    authors: Tefferi A,Murphy S

    更新日期:2001-09-01 00:00:00

  • Congenital platelet disorders.

    abstract::Congenital platelet disorders include thrombocytopathies and thrombocytopenias, which often occur in association. Thrombocytopathies constitute a model for exploring platelet physiology at the molecular level: adhesion, activation, release phenomena, aggregation. Further advances in understanding thrombocytopenias now...

    journal_title:Blood reviews

    pub_type: 杂志文章,评审

    doi:10.1016/0268-960x(88)90004-5

    authors: Bellucci S,Caen JP

    更新日期:1988-03-01 00:00:00

  • Modifying perioperative blood loss.

    abstract::Fears about the risks of disease transmission through the transfusion of homologous blood, as well as problems with blood supply and cost have increased the interest in reducing perioperative bleeding. This article discusses the causes of non-surgical perioperative bleeding and attempts to reduce perioperative bleedin...

    journal_title:Blood reviews

    pub_type: 杂志文章,评审

    doi:10.1016/0268-960x(91)90034-a

    authors: Hunt BJ

    更新日期:1991-09-01 00:00:00

  • Molecular diagnosis of haematological neoplasms.

    abstract::DNA analysis has become of practical value in the diagnosis and classification of leukaemias and lymphomas. This is exemplified by the study of lymphoproliferative disorders using immunoglobulin and T-cell receptor gene probes for the determination of clonality and cell lineage. Chromosomal analysis with DNA probes is...

    journal_title:Blood reviews

    pub_type: 杂志文章,评审

    doi:10.1016/0268-960x(88)90028-8

    authors: Fey MF,Wainscoat JS

    更新日期:1988-06-01 00:00:00

  • Thrombopoietic agents.

    abstract::Thrombopoietin (TPO) is the key cytokine involved in thrombopoiesis, and is the endogenous ligand for the thrombopoietin receptor that is expressed on the surface of platelets, megakaryocytes, and megakaryocytic precursors. First-generation thrombopoietic agents were recombinant forms of human TPO, and their developme...

    journal_title:Blood reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.blre.2010.04.002

    authors: Stasi R,Bosworth J,Rhodes E,Shannon MS,Willis F,Gordon-Smith EC

    更新日期:2010-07-01 00:00:00

  • The regulation of megakaryocytopoiesis.

    abstract::The process of megakaryocytopoiesis begins with the commitment of a pluripotent hematopoietic stem cell to a differentiation pathway that culminates in the release of mature platelets into the circulation. A variety of megakaryocyte precursor cells have been identified after stem cell commitment has occurred and these...

    journal_title:Blood reviews

    pub_type: 杂志文章,评审

    doi:10.1016/0268-960x(95)90034-9

    authors: Ellis MH,Avraham H,Groopman JE

    更新日期:1995-03-01 00:00:00

  • Therapeutic strategies in low and high-risk MDS: What does the future have to offer?

    abstract::Myelodysplastic syndromes (MDS) are a heterogeneous group of myeloid disorders characterized by cytopenias and increased risk of acute leukemia transformation. Prognosis of MDS patients can be assessed by various scoring systems, the most common being the International Prognostic Scoring System (IPSS) now refined by t...

    journal_title:Blood reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.blre.2020.100689

    authors: Scalzulli E,Pepe S,Colafigli G,Breccia M

    更新日期:2020-03-31 00:00:00

  • DNA hypomethylation therapy for hemoglobin disorders: molecular mechanisms and clinical applications.

    abstract::Reactivation of fetal hemoglobin (HbF) expression is an important therapeutic option in patients with hemoglobin disorders. In sickle cell disease (SCD), an increase in HbF would interfere with the polymerization of sickle hemoglobin while in beta-thalassemia, an increase in gamma-globin chain synthesis would decrease...

    journal_title:Blood reviews

    pub_type: 杂志文章

    doi:10.1016/j.blre.2006.01.002

    authors: Fathallah H,Atweh GF

    更新日期:2006-07-01 00:00:00

  • RhD haemolytic disease of the fetus and the newborn.

    abstract::When an RhD negative mother is exposed to the RhD positive red cells (usually as transplacental haemorrhage), she develops allo-anti-D which crosses the placenta and then results in the destruction of fetal red cells. Clinical manifestations of RhD haemolytic disease (HDN) range from asymptomatic mild anaemia to hydro...

    journal_title:Blood reviews

    pub_type: 杂志文章,评审

    doi:10.1054/blre.1999.0123

    authors: Urbaniak SJ,Greiss MA

    更新日期:2000-03-01 00:00:00

  • Mobilizing the older patient with myeloma.

    abstract::Although hematopoietic progenitor/stem cells (HPC) have been used for autologous transplants for approximately 25 years, it is only recently that we have begun to finally understand the factors which play important roles in causing these cells to leave their marrow niches and circulate in the blood. Still less is unde...

    journal_title:Blood reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.blre.2005.06.001

    authors: Cottler-Fox M,Lapidot T

    更新日期:2006-01-01 00:00:00

  • Intensive chemotherapy in myelodysplastic syndromes.

    abstract::Patients with myelodysplastic syndrome (MDS) who have more than 10% blasts in their bone marrow have a very short survival. Treatment has not improved for these patients for the past 10 years and supportive care alone is still the gold standard. Intensive chemotherapy for poor prognosis MDS has been little tried, but ...

    journal_title:Blood reviews

    pub_type: 杂志文章,评审

    doi:10.1016/0268-960x(92)90017-k

    authors: Hamblin TJ

    更新日期:1992-12-01 00:00:00

  • Duration of anticoagulation: decision making based on absolute risk.

    abstract::We are often faced with the question as to the optimum duration of secondary prophylaxis with oral anticoagulants after an episode of venous thromboembolism. Theoretically if we know the recurrence rate, the case-fatality, the effectiveness of oral anticoagulant therapy, and the rate of fatal haemorrhage on treatment,...

    journal_title:Blood reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.blre.2005.09.001

    authors: Keeling D

    更新日期:2006-05-01 00:00:00